Cough.
On Days 1-5 of the study, horses received eight “actuations” twice daily. On Days 6-10 horses received 12 actuations once daily.
In total, data from 223 horses were available for the team to assess safety, and data from 220 horses to assess efficacy.
“In terms of safety, only 11 adverse events were identified in five horses in the ciclesonide group,” said Pirie. This was not significantly different than the 13 adverse events identified in eight horses in the placebo group.”
Next, the team determined efficacy, defined as a ≥30% reduction in WCS between Day 0 and Day 10. In the ciclesonide group 73.4% of the horses showed a ≥30% improvement in WCS, a responder rate significantly greater than the 43.2% recorded in the placebo group.